Rovadicitinib not checked
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · TQ05105
FollowEvery change as it happens, and a Monday email
Trials
8 active
17 in total
What this is
- How it works
- Blocks JAK enzymes that pass on immune signals, to calm an overactive immune system.-citinib: Janus kinase inhibitors WHO name stem
- How it’s given
- “Rovadicitinib is an inhibitor of Janus associated kinases (JAK) family and Rho associated kinases (ROCK). It can inhibit the sustained abnormal activation of the Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway and also inhibit Rho associated kinase 2 (ROCK2). The JAK 1-JAK 2 signaling pathway is a key step in causing inflammation and tissue damage in acute…”In the company’s words, NCT06682169 on ClinicalTrials.gov
- Tested for
- Myelofibrosis (5 trials), Chronic Graft Versus Host Disease (2 trials), Graft-versus-host Disease
- Main trialPhase 3
- “The aim of this study is to demonstrate that in subjects with moderate to severe chronic graft-versus-host disease in the third line and beyond, the use of rosuvastatin compared to the protocol chosen by the researchers can significantly improve the objective response rate of subjects at week 24.”In the company’s words, NCT06682169 on ClinicalTrials.gov
- Other names
- TQ05105
Other drugs for Myelofibrosis
- NavitoclaxAbbVie · Phase 3
- NavtemadlinKartos Therapeutics, Inc. · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 3
- Ropeginterferon alfa-2bPharmaEssentia · Phase 3
- ElriterceptTakeda · Phase 3
- PelabresibNovartis · Phase 3
Coming up6
- DecPhase 1/2 trial completes · ClinicalTrials.gov
- DecPhase 1 trial completes · ClinicalTrials.gov
- DecPhase 1 trial completes · ClinicalTrials.gov
- Nov 2027Phase 2 trial completes · ClinicalTrials.gov
- Jun 2028Phase 2 trial completes · ClinicalTrials.gov
- Oct 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials17
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Oct 2029 | Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease | |
| Phase 2Recruiting | Nov 2027 | A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease | |
| Phase 2Recruiting | Jun 2028 | A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis | |
| Phase 1/2Active, not recruiting | 30 Jun 2023 | A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease | |
| Phase 1/2Recruiting | Dec 2026 | A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) | |
| Phase 1Recruiting | Oct 2026 | To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects | |
| Phase 1Active, not recruiting | Dec 2026 | Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets | |
| Phase 1Active, not recruiting | Dec 2026 | QT Interval/Corrected QT Interval (QT/QTc) Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants | |
| Phase 2Completed | 15 Oct 2023 | A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis | |
| Phase 1/2Terminated | 10 Jul 2023 | A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD) | |
| Phase 1/2Terminated | 30 Dec 2025 | A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) | |
| Phase 1Completed | 28 Jul 2021 | To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects | |
| Phase 1Completed | 17 Mar 2023 | A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms | |
| Phase 1Completed | 29 Jan 2024 | A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets | |
| Phase 1Completed | 8 Apr 2024 | A Clinical Trial of Mass Balance of [14C] TQ05105 in Healthy Chinese Subjects | |
| Phase 1Completed | 17 Mar 2025 | To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects | |
| Phase 1Terminated | 12 Aug 2025 | TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026